Goods & Services

Medical and scientific research, namely, analysis of imaging, genomic and molecular data using artificial intelligence; medical and scientific research services, namely, analysis of next generation sequencing data for genomic DNA and RNA transcripts using artificial intelligence Medical analysis of imaging, genomic and molecular data using artificial intelligence; medical testing services, namely, analysis of next generation sequencing data for genomic DNA and RNA transcripts using artificial intelligence

Goods & Services

Medical and scientific research, namely, analysis of imaging, genomic and molecular data using artificial intelligence; medical and scientific research services, namely, analysis of next generation sequencing data for genomic DNA and RNA transcripts using artificial intelligence Medical analysis of imaging, genomic and molecular data using artificial intelligence; medical testing services, namely, analysis of next generation sequencing data for genomic DNA and RNA transcripts using artificial intelligence

Abstract

Systems, apparatuses, and methods as described herein can provide in part a validated AI model integrated with tumor profiling that enhances diagnostic accuracy, including resolution of CUP cases, and prompts clinically relevant therapeutic recommendation changes without requiring additional specimen. Machine learning models in a hierarchal sample type tree can be used, e.g., to determine a tumor type of a cancer.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G06N 20/00 - Machine learning

Goods & Services

Medical and scientific research; providing information about medical and scientific research; Medical and scientific research in the field of biomarker discovery services Medical services; medical screening services; medical diagnostic testing, monitoring and reporting services; provision of medical information via a website

Abstract

Techniques are provided for accurately detecting a mutation in a cell-free nucleic acid shed from a tissue (e.g., a tumor) into blood. An example technique can distinguish between a mutation in a cell-free nucleic acid molecule derived from blood cells and a mutation in a cell-free nucleic acid molecule derived from a tumor. A cell-free sample (e.g., plasma or serum) and a cellular sample (e.g., white blood cells in a buffy coat) can be sequenced. After applying filtering criteria to respective sets of sequence reads, a particular mutation can be detected in both the cell-free sample and the cellular sample. Confidence intervals for the detection of the mutation can be determined for both samples, with an upper bound for the cellular sample and a lower bound of the cell-free sample being used to determine the origin of the mutation in the cell-free sample.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6869 - Methods for sequencing

Goods & Services

Providing a website featuring non-downloadable software using artificial intelligence for the diagnosis, detection, screening, disease monitoring, treatment monitoring and therapy selection in the field of cancer; medical analysis of genomic and molecular data using artificial intelligence for the diagnosis, detection, screening, disease monitoring, treatment monitoring and therapy selection in the field of cancer Medical research, namely, assessment of genomic and molecular data using artificial intelligence

Goods & Services

Providing a website featuring non-downloadable software using artificial intelligence for the diagnosis, detection, screening, disease monitoring, treatment monitoring and therapy selection in the field of cancer; medical analysis of genomic and molecular data using artificial intelligence for the diagnosis, detection, screening, disease monitoring, treatment monitoring and therapy selection in the field of cancer Medical research, namely, assessment of genomic and molecular data using artificial intelligence

Goods & Services

Medical and scientific research in the field of oncology; providing medical and scientific research information in the field of oncology; medical and scientific research, namely, whole genome and whole transcriptome sequencing assays for biomarker detection ¬and analysis in patients with leukemia, lymphoma, myeloma, or other hematologic malignancies Medical testing for diagnostic, prognostic, or treatment purposes; medical testing, namely, whole genome and whole transcriptome sequencing assays for biomarker detection in patients with leukemia, lymphoma, myeloma, or other hematologic malignancies

Goods & Services

Promoting collaboration within the scientific, research and medical communities to optimize clinical care and outcomes for cancer patients, identify predictive and prognostic markers to further advance molecular profiling and cancer care, promote clinical trials, generate scientific publications, and generate and document additional medical evidence for the appropriate use and impact of molecular profiling for cancer; Promoting the exchange of information and resources within the scientific research and medical communities to optimize clinical care and outcomes for cancer patients, identify predictive and prognostic markers to further advance molecular profiling and cancer care, promote clinical trials, generate scientific publications, and generate and document additional medical evidence for the appropriate use and impact of molecular profiling for cancer medical research services in the field of cancer; providing a database of combined clinical-genomic data including clinical outcomes for research; organizing meetings for the purpose of collaborating on cancer research

Goods & Services

Promoting collaboration within the scientific, research and medical communities to optimize clinical care and outcomes for cancer patients, identify predictive and prognostic markers to further advance molecular profiling and cancer care, promote clinical trials, generate scientific publications, and generate and document additional medical evidence for the appropriate use and impact of molecular profiling for cancer; Promoting the exchange of information and resources within the scientific research and medical communities to optimize clinical care and outcomes for cancer patients, identify predictive and prognostic markers to further advance molecular profiling and cancer care, promote clinical trials, generate scientific publications, and generate and document additional medical evidence for the appropriate use and impact of molecular profiling for cancer medical research services in the field of cancer; providing a database of combined clinical-genomic data including clinical outcomes for research; organizing meetings for the purpose of collaborating on cancer research

Goods & Services

Promoting collaboration within the scientific, research and medical communities to optimize clinical care and outcomes for cancer patients, identify predictive and prognostic markers to further advance molecular profiling and cancer care, promote clinical trials, generate scientific publications, and generate and document additional medical evidence for the appropriate use and impact of molecular profiling for cancer; Promoting the exchange of information and resources within the scientific research and medical communities to optimize clinical care and outcomes for cancer patients, identify predictive and prognostic markers to further advance molecular profiling and cancer care, promote clinical trials, generate scientific publications, and generate and document additional medical evidence for the appropriate use and impact of molecular profiling for cancer medical research services in the field of cancer; providing a database of combined clinical-genomic data including clinical outcomes for research; organizing meetings for the purpose of collaborating on cancer research

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that strongly correlate with response of colorectal cancer patients to FOLFOX. Described herein are data structures, data processing, and machine learning models to predict effectiveness of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising administration of 5-fluorouracil/leucovorin combined with oxaliplatin (FOLFOX) or with irinotecan (FOLFIRI).

IPC Classes  ?

• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G06N 20/00 - Machine learning
• G06N 20/20 - Ensemble learning
• G16B 20/10 - Ploidy or copy number detection
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Goods & Services

Providing medical and scientific research information to researchers, patients and medical professionals in the form of reports in the field of molecular profiling for the characterization of cancer, e.g., genomic and transcriptomic characteristics, tumor microenvironment, and determination of biosignatures using bioinformatics and artificial intelligence; providing medical research information in the field of cancer based on next-generation sequencing (NGS), including whole exome sequencing (WES), whole transcriptome sequencing (WTS), and whole genome sequencing (WGS) Providing medical information to patients and medical professionals in the form of reports in the field of molecular profiling for the diagnosis, treatment and monitoring of cancer; providing medical information in the field of cancer based on next-generation sequencing (NGS), including whole exome sequencing (WES), whole transcriptome sequencing (WTS), and whole genome sequencing (WGS)

Goods & Services

Providing medical and scientific research information to researchers, patients and medical professionals in the form of reports in the field of molecular profiling for the characterization of cancer, genomic and transcriptomic characteristics, tumor microenvironment, and determination of biosignatures using bioinformatics and artificial intelligence; providing medical research information in the field of cancer based on next-generation sequencing (NGS), including whole exome sequencing (WES), whole transcriptome sequencing (WTS), and whole genome sequencing (WGS) Providing medical information to patients and medical professionals in the form of reports in the field of molecular profiling for the diagnosis, treatment and monitoring of cancer; providing medical information in the field of cancer based on next-generation sequencing (NGS), including whole exome sequencing (WES), whole transcriptome sequencing (WTS), and whole genome sequencing (WGS)

Goods & Services

Providing medical and scientific research information to researchers, patients and medical professionals in the form of reports in the field of molecular profiling for the characterization of cancer, e.g., genomic and transcriptomic characteristics, tumor microenvironment, and determination of biosignatures using bioinformatics and artificial intelligence; providing medical research information in the field of cancer based on next-generation sequencing (NGS), including whole exome sequencing (WES), whole transcriptome sequencing (WTS), and whole genome sequencing (WGS) Providing medical information to patients and medical professionals in the form of reports in the field of molecular profiling for the diagnosis, treatment and monitoring of cancer; providing medical information in the field of cancer based on next-generation sequencing (NGS), including whole exome sequencing (WES), whole transcriptome sequencing (WTS), and whole genome sequencing (WGS)

Goods & Services

Medical research services in the field of cancer treatment; providing medical research information, namely, using artificial intelligence to predict promoter methylation of the MGMT (O6-methylguanine-DNA methyltransferase ) gene and therapeutic response of cancers to related therapies. Medical analysis of genomic and transcriptomic data using artificial intelligence to predict promoter methylation of the MGMT (O6-methylguanine-DNA methyltransferase ) gene and therapeutic response of cancers to related therapies.

Goods & Services

Medical and scientific research; medical and scientific research services in the fields of anatomic pathology, molecular profiling, blood-based diagnostics, oncology, genomics, and proteomics; pharmaceutical research and development; genetic and proteomic research studies of specimens; genetic and proteomic research studies of specimens, namely, next-generation sequencing, whole exome sequencing, whole transcriptome sequencing, whole genome sequencing, mass spectrometry, genetic signatures, specific genetic targets, DNA/RNA isolation and western blot analysis, facilitating effective clinical trials, product development, and research using large amounts of biospecimens and associated research and patient data; providing medical and scientific research in the fields of oncology, and molecular profiling, genomics and proteomics; conducting clinical trials; Medical research laboratory services; medical research laboratory services, namely, analysis of individualized patient data to aid physicians in determining diagnostic, therapeutic and prognostic objectives for patients; medical research laboratory services, namely, providing patient reports based on analysis of RNA, DNA and protein to aid physicians in determining diagnosis, including screening and early detection, prognosis, and predicting or monitoring residual disease, recurrence and/or therapeutic response for cancer patients; providing a centralized database in the field of molecular diagnostics to allow oncologists to acquire and share molecular tumor profiling information and clinical outcomes within a collaborative, secured environment, all for treatment and diagnostic purposes medical screening services; medical diagnostic testing, monitoring and reporting services; pathology diagnostic services; prognostic analysis services; theranostic analysis services

Goods & Services

Medical and scientific research; medical and scientific research services in the fields of anatomic pathology, molecular profiling, blood-based diagnostics, oncology, genomics, and proteomics; pharmaceutical research and development; genetic and proteomic research studies of specimens; genetic and proteomic research studies of specimens, namely, next-generation sequencing, whole exome sequencing, whole transcriptome sequencing, whole genome sequencing, mass spectrometry, genetic signatures, specific genetic targets, DNA/RNA isolation and western blot analysis, facilitating effective clinical trials, product development, and research using large amounts of biospecimens and associated research and patient data; providing medical and scientific research in the fields of oncology, and molecular profiling, genomics and proteomics; conducting clinical trials; Medical research laboratory services; medical research laboratory services, namely, analysis of individualized patient data to aid physicians in determining diagnostic, therapeutic and prognostic objectives for patients; medical research laboratory services, namely, providing patient reports based on analysis of RNA, DNA and protein to aid physicians in determining diagnosis, including screening and early detection, prognosis, and predicting or monitoring residual disease, recurrence and/or therapeutic response for cancer patients; providing a centralized database in the field of molecular diagnostics to allow oncologists to acquire and share molecular tumor profiling information and clinical outcomes within a collaborative, secured environment, all for treatment and diagnostic purposes medical screening services; medical diagnostic testing, monitoring and reporting services; pathology diagnostic services; prognostic analysis services; theranostic analysis services

Goods & Services

Genomic and molecular medical testing services for diagnostic or treatment purposes in the field of cancer; diagnostic services, namely, medical diagnostic testing for cancer and other diseases and disorders; providing collected and analyzed medical information in the field of genetic and treatment information for cancer and other diseases and disorders for diagnostic and treatment purposes; providing medical data and information to healthcare professionals.

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be used to train machine learning models using disease outcomes This approach has been applied to train machine learning models that predict metastatic potential.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G06N 5/00 - Computing arrangements using knowledge-based models
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Goods & Services

Medical screening services in the field of cancer; medical analysis of blood tests for cancer screening using artificial intelligence.

Goods & Services

Medical research, namely, assessment of clinical data; medical research, namely, assessment of molecular profiling data, clinical data, and outcomes data to better understand cancer and treatment thereof. Medical screening services in the field of cancer; medical diagnostic testing, monitoring and reporting services in the field of cancer; pathology diagnostic services for medical purposes in the field of cancer; prognostic analysis services for medical purposes; theranostic analysis services for medical purposes; molecular diagnostic services for medical purposes.

Goods & Services

Medical analysis services relating to the treatment of patients; medical analysis of genomic and molecular data using artificial intelligence to identify tissue of cancer origin.

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for the disease, such as treatments that provide potential benefit or potential lack of benefit for the disease. Molecular profiling can include biomarkers for immune checkpoint therapy, including microsatellite instability, tumor mutational burden, mismatch repair, and expression of checkpoint proteins such as PD-L1.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• G16B 20/10 - Ploidy or copy number detection
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 30/10 - Sequence alignmentHomology search
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Goods & Services

Genomic and molecular medical testing services for diagnostic or treatment purposes in the field of cancer; diagnostic services, namely, medical diagnostic testing for cancer and other diseases and disorders; providing collected and analyzed medical information in the field of genetic and treatment information for cancer and other diseases and disorders for diagnostic and treatment purposes; providing medical data and information to healthcare professionals

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that correlate with response of cancer patients to platinum-based chemotherapy. Described herein are data structures, data processing, and machine learning models to predict a probability of benefit of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising platinum therapy.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G06N 3/084 - Backpropagation, e.g. using gradient descent
• G06N 20/00 - Machine learning
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Goods & Services

Medical screening services in the field of cancer; medical analysis of blood tests for cancer screening using artificial intelligence

Goods & Services

Medical research, namely, assessment of clinical data; Medical research, namely, assessment of molecular profiling data, clinical data, and outcomes data to better understand cancer and treatment thereof Medical screening services in the field of cancer; medical diagnostic testing, monitoring and reporting services in the field of cancer; pathology diagnostic services for medical purposes in the field of cancer; prognostic analysis services for medical purposes; theranostic analysis services for medical purposes; molecular diagnostic services for medical purposes

Goods & Services

Medical analysis services relating to the treatment of patients; medical analysis of genomic and molecular data using artificial intelligence to identify tissue of cancer origin

Goods & Services

Medical research, namely, assessment of clinical data; medical research, namely, assessment of molecular profiling data, clinical data, and outcomes data to better understand cancer and treatment thereof. Medical screening services in the field of cancer; medical diagnostic testing, monitoring and reporting services in the field of cancer; pathology diagnostic services for medical purposes in the field of cancer; prognostic analysis services for medical purposes; theranostic analysis services for medical purposes; molecular diagnostic services for medical purposes.

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that predict cancer patient benefit from PARP inhibitors.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Goods & Services

Liquid biopsy testing for cancer cells using predictive markers and signatures directed to exome and transcriptome molecular profiling and biopsy testing assays using circulating nucleic acids sequencing (cNAS) for analysis of Whole Exome (cfDNA) and Whole Transcriptome (cfRNA) genes.

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that predict cancer patient benefit from immunotherapy such as checkpoint inhibitor therapy.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be used to train machine learning models using disease outcomes to identify biomarker signatures that can provide a prediction of such outcomes. This approach has been applied to identify biomarker signatures and machine learning models that can predict metastatic potential.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16B 40/20 - Supervised data analysis
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Goods & Services

Liquid biopsy testing for cancer cells using predictive markers and signatures directed to exome and transcriptome molecular profiling and biopsy testing assays using circulating nucleic acids sequencing (cNAS) for analysis of Whole Exome (cfDNA) and Whole Transcriptome (cfRNA) genes

Goods & Services

Genomic and molecular medical testing services for diagnostic or treatment purposes in the field of cancer; diagnostic services, namely, medical diagnostic testing for cancer and other diseases and disorders; providing collected and analyzed medical information in the field of genetic and treatment information for cancer and other diseases and disorders for diagnostic and treatment purposes; providing medical data and information to healthcare professionals.

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that predict cancer patient benefit from immunotherapy such as checkpoint inhibitor therapy.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• G16B 40/20 - Supervised data analysis

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.

IPC Classes  ?

• G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
• C40B 60/12 - Apparatus specially adapted for use in combinatorial chemistry or with libraries for screening libraries
• C12Q 1/6841 - In situ hybridisation
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• G16B 50/30 - Data warehousingComputing architectures
• G16H 70/40 - ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
• G16B 20/10 - Ploidy or copy number detection
• G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G16B 35/00 - ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• G16B 20/40 - Population geneticsLinkage disequilibrium
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16B 99/00 - Subject matter not provided for in other groups of this subclass
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16B 30/10 - Sequence alignmentHomology search
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• B01L 7/00 - Heating or cooling apparatusHeat insulating devices
• G16C 20/60 - In silico combinatorial chemistry
• G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 50/00 - ICT programming tools or database systems specially adapted for bioinformatics
• G16B 25/00 - ICT specially adapted for hybridisationICT specially adapted for gene or protein expression
• G16B 45/00 - ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. Here, we used molecular profiling data to identify biomarker signatures (biosignatures) that predict a tumor primary lineage, cancer category or type, organ group and/or histology. The signature may use genomic and transcriptome level information.

IPC Classes  ?

• G06N 20/20 - Ensemble learning
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Goods & Services

Genomic and molecular medical testing services for diagnostic or treatment purposes in the field of cancer; diagnostic services, namely, medical diagnostic testing for cancer and other diseases and disorders; providing collected and analyzed medical information in the field of genetic and treatment information for cancer and other diseases and disorders for diagnostic and treatment purposes; providing medical data and information to healthcare professionals.

Goods & Services

Medical and scientific research and analysis services in the field of molecular biology, namely, analyzing molecular data with multiphasic clustering to produce novel insights to characterize new patterns that better define disease, identify new drug targets, and unlock multidimensional associations.

Goods & Services

Genomic and molecular medical testing services for diagnostic or treatment purposes in the field of cancer; diagnostic services, namely, medical diagnostic testing for cancer and other diseases and disorders; providing collected and analyzed medical information in the field of genetic and treatment information for cancer and other diseases and disorders for diagnostic and treatment purposes; providing medical data and information to healthcare professionals

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that correlate with response of cancer patients to platinum-based chemotherapy. Described herein are data structures, data processing, and machine learning models to predict a probability of benefit of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising platinum therapy.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• G06N 20/00 - Machine learning
• G06N 3/084 - Backpropagation, e.g. using gradient descent
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that strongly correlate with response of colorectal cancer patients to FOLFOX. Described herein are data structures, data processing, and machine learning models to predict effectiveness of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising administration of 5-fluorouracil/leucovorin combined with oxaliplatin (FOLFOX) or with irinotecan (FOLFIRI).

IPC Classes  ?

• G06N 20/20 - Ensemble learning
• G06N 20/00 - Machine learning
• G16B 20/10 - Ploidy or copy number detection
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that predict cancer patient benefit from PARP inhibitors.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that predict cancer patient benefit from PARP inhibitors.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that predict cancer patient benefit from immunotherapy such as checkpoint inhibitor therapy.

IPC Classes  ?

• C12Q 1/6869 - Methods for sequencing
• G16B 20/10 - Ploidy or copy number detection
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that predict cancer patient benefit from immunotherapy such as checkpoint inhibitor therapy.

IPC Classes  ?

• G16B 20/10 - Ploidy or copy number detection
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• C12Q 1/6869 - Methods for sequencing

Goods & Services

Medical and scientific research and analysis services in the field of molecular biology, namely, analyzing molecular data with multiphasic clustering to produce novel insights to characterize new patterns that better define disease, identify new drug targets, and unlock multidimensional associations

Goods & Services

Genomic and molecular medical testing services for diagnostic or treatment purposes in the field of cancer; diagnostic services, namely, medical diagnostic testing for cancer and other diseases and disorders; providing collected and analyzed medical information in the field of genetic and treatment information for cancer and other diseases and disorders for diagnostic and treatment purposes; providing medical data and information to healthcare professionals

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. Here, we used molecular profiling data to identify biomarker signatures that predict a tumor primary lineage or organ group.

IPC Classes  ?

• G16B 40/20 - Supervised data analysis
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G06N 20/20 - Ensemble learning

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be used to train machine learning models using disease outcomes to identify biomarker signatures that can provide a prediction of such outcomes. This approach has been applied to identify biomarker signatures and machine learning models that can predict metastatic potential.

IPC Classes  ?

• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be used to train machine learning models using disease outcomes to identify biomarker signatures that can provide a prediction of such outcomes. This approach has been applied to identify biomarker signatures and machine learning models that can predict metastatic potential.

IPC Classes  ?

• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Goods & Services

Medical research, namely, assessment of clinical data; Medical research, namely, assessment of molecular profiling data, clinical data, and outcomes data to better understand cancer and treatment thereof Medical screening services in the field of cancer; medical diagnostic testing, monitoring and reporting services in the field of cancer; pathology diagnostic services for medical purposes in the field of cancer; prognostic analysis services for medical purposes; theranostic analysis services for medical purposes; molecular diagnostic services for medical purposes

Goods & Services

Medical analysis services relating to the treatment of patients, namely, medical analysis of genomic and molecular data for the treatment of cancer

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that predict cancer patient benefit from immunotherapy such as checkpoint inhibitor therapy.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that predict cancer patient benefit from immunotherapy such as checkpoint inhibitor therapy.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)

Goods & Services

Research services, namely, providing a database in the field of molecular profiling to allow users to acquire, utilize, access, analyze, or share molecular tumor profiling derived information including clinical outcomes within a collaborative, secured environment all for scientific research and drug development purposes; providing a website featuring non-downloadable software using artificial intelligence for the research and development of cancer treatments and protocols Healthcare and medical services, namely, providing a database in the field of molecular profiling to allow users to acquire, utilize, access, analyze, or share molecular tumor profiling derived information including clinical outcomes within a collaborative, secured environment all for treatment and diagnostic purposes

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that strongly correlate with response of colorectal cancer patients to FOLFOX. Described herein are data structures, data processing, and machine learning models to predict effectiveness of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising administration of 5-fluorouracil/leucovorin combined with oxaliplatin (FOLFOX) or with irinotecan (FOLFIRI).

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G06N 20/00 - Machine learning
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• G16B 20/10 - Ploidy or copy number detection

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. Here, we used molecular profiling data to identify biomarker signatures (biosignatures) that predict a tumor primary lineage, cancer category or type, organ group and/or histology. The signature may use genomic and transcriptome level information.

IPC Classes  ?

• G06N 20/00 - Machine learning
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. Here, we used molecular profiling data to identify biomarker signatures (biosignatures) that predict a tumor primary lineage, cancer category or type, organ group and/or histology. The signature may use genomic and transcriptome level information.

IPC Classes  ?

• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• G06N 20/00 - Machine learning
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• G06N 3/08 - Learning methods
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that correlate with response of cancer patients to platinum-based chemotherapy. Described herein are data structures, data processing, and machine learning models to predict a probability of benefit of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising platinum therapy.

IPC Classes  ?

• C12Q 1/6804 - Nucleic acid analysis using immunogens
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6813 - Hybridisation assays

Goods & Services

Medical analysis services relating to the treatment of patients, namely, medical analysis of genomic and molecular data for the treatment of cancer

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments that have likely benefit for a cancer, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease. The molecular profiling can be used to identify likely have lack of benefit for treating the cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 25/00 - ICT specially adapted for hybridisationICT specially adapted for gene or protein expression
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6869 - Methods for sequencing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Goods & Services

Genomic and molecular medical testing services for diagnostic or treatment purposes in the field of cancer; diagnostic services, namely, medical diagnostic testing for cancer and other diseases and disorders; providing collected and analyzed medical information in the field of genetic and treatment information for cancer and other diseases and disorders for diagnostic and treatment purposes; providing medical data and information to healthcare professionals

Goods & Services

Medical prognostic analysis services for medical purposes relative to cancer; medical theranostic analysis services in the nature of generating cancer treatment selection reports for others based on tumor molecular profiling, namely, the generation of tumor theranostic profiling reports containing therapies relative to cancer for patients and their physicians

Abstract

Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that strongly correlate with response of colorectal cancer patients to FOLFOX. Described herein are data structures, data processing, and machine learning models to predict effectiveness of a treatment for a disease or disorder of a subject having a particular set of biomarkers, as well as an exemplary application of such a model to precision medicine, e.g., to methods for selecting a treatment based on a molecular profile, e.g., a treatment comprising administration of 5-fluorouracil/leucovorin combined with oxaliplatin (FOLFOX) or with irinotecan (FOLFIRI).

IPC Classes  ?

• G06N 20/00 - Machine learning
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06N 5/02 - Knowledge representationSymbolic representation
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training

Goods & Services

Genomic and molecular medical testing for cancer and other diagnostic or treatment purposes; diagnostic services, namely, medical diagnostic testing for cancer and other diseases and disorders; providing collected and analyzed medical information in the field of genetic and treatment information for cancer and other diseases and disorders for diagnostic and treatment purposes; providing medical data and information to healthcare professionals; molecular medical testing for cancer using comparison of genomic characteristics of test sample with database of known characteristics

Goods & Services

Medical screening services in the field of oncology related clinical trials

Goods & Services

Providing use of non-downloadable software for use in connection with research management services for physicians and patients, namely, research management services for enrolling patients in medical clinical trials; providing use of non-downloadable software for use in connection with patient screening and recruitment services for oncology related clinical trials; providing use of non-downloadable software for use in connection with oncology clinical trial site activation

Goods & Services

Medical screening services in the field of oncology related clinical trials

Goods & Services

Medical research services, namely, providing medical, genetic, and genomic information and data for scientific, laboratory, and medical research and development purposes Genomic and molecular medical testing services for diagnostic or treatment purposes in the field of cancer; diagnostic services, namely, medical diagnostic testing for cancer and other diseases and disorders; providing collected and analyzed medical information in the field of genetic and treatment information for cancer and other diseases and disorders for diagnostic and treatment purposes; providing medical data and information to healthcare professionals

Goods & Services

Medical research services, namely, providing medical, genetic, and genomic information and data for scientific, laboratory, and medical research and development purposes Genomic and molecular medical testing services for diagnostic or treatment purposes in the field of cancer; diagnostic services, namely, medical diagnostic testing for cancer and other diseases and disorders; providing collected and analyzed medical information in the field of genetic and treatment information for cancer and other diseases and disorders for diagnostic and treatment purposes; providing medical data and information to healthcare professionals

Goods & Services

Providing collected and analyzed medical information in the field of genetic and treatment information for cancer and other diseases and disorders for diagnostic and treatment purposes; providing medical data and information to healthcare professionals

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for the disease, such as treatments that provide potential benefit or potential lack of benefit for the disease. Molecular profiling can include biomarkers for immune checkpoint therapy, including microsatellite instability, tumor mutational burden, mismatch repair, and expression of checkpoint proteins such as PD-L1.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/6858 - Allele-specific amplification

Goods & Services

Genomic and molecular medical testing for cancer and other diagnostic or treatment purposes; diagnostic services, namely, medical diagnostic testing for cancer and other diseases and disorders; providing collected and analyzed medical information in the field of genetic and treatment information for cancer and other diseases and disorders for diagnostic and treatment purposes; providing medical data and information to healthcare professionals

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for the disease, such as treatments that provide likely benefit or likely lack of benefit for the disease. The molecular profiling can include analysis of a sequence of a nucleic acid. The invention provides a method of identifying at least one treatment associated with a cancer in a subject. In still another related aspect, the invention provides use of a reagent in carrying out the methods of the invention, and/or use of a reagent in the manufacture of a reagent or kit for carrying out the methods of the invention. In an aspect, the invention provides a system for identifying at least one treatment associated with a cancer in a subject.

IPC Classes  ?

• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for the disease, such as treatments that provide likely benefit or likely lack of benefit for the disease. The molecular profiling can include analysis of immune modulators such as PD-1 and/or its ligand PD-L1.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G06F 19/24 - for machine learning, data mining or biostatistics, e.g. pattern finding, knowledge discovery, rule extraction, correlation, clustering or classification
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• G06F 19/10 - Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology (in silico methods of screening virtual chemical libraries C40B 30/02;in silico or mathematical methods of creating virtual chemical libraries C40B 50/02)
• G06F 19/18 - for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
• C40B 30/02 - In silico screening
• C40B 60/12 - Apparatus specially adapted for use in combinatorial chemistry or with libraries for screening libraries
• G06F 19/22 - for sequence comparison involving nucleotides or amino acids, e.g. homology search, motif or Single-Nucleotide Polymorphism [SNP] discovery or sequence alignment
• B01L 7/00 - Heating or cooling apparatusHeat insulating devices
• G06F 19/20 - for hybridisation or gene expression, e.g. microarrays, sequencing by hybridisation, normalisation, profiling, noise correction models, expression ratio estimation, probe design or probe optimisation
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

A system and method for determining individualized medical intervention for a particular disease state, and especially for cancers, that includes the molecular profiling of a biological sample from the patient, determining whether any molecular findings including one or more genes, one or more gene expressed proteins, one or more molecular mechanisms, and/or combinations of such exhibit a change in expression compared to a reference, and identifying a non-specific disease therapy or agent capable of interacting with the genes, gene expressed proteins, molecular mechanisms, or combinations of such molecular findings that exhibited a change in expression.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G06F 19/20 - for hybridisation or gene expression, e.g. microarrays, sequencing by hybridisation, normalisation, profiling, noise correction models, expression ratio estimation, probe design or probe optimisation
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G06F 19/18 - for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
• G06F 19/28 - for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures

Abstract

A system and method for determining individualized medical intervention for a particular disease state, and especially for cancers, that includes the molecular profiling of a biological sample from the patient, determining whether any molecular findings including one or more genes, one or more gene expressed proteins, one or more molecular mechanisms, and/or combinations of such exhibit a change in expression compared to a reference, and identifying a non-specific disease therapy or agent capable of interacting with the genes, gene expressed proteins, molecular mechanisms, or combinations of such molecular findings that exhibited a change in expression.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G06F 19/20 - for hybridisation or gene expression, e.g. microarrays, sequencing by hybridisation, normalisation, profiling, noise correction models, expression ratio estimation, probe design or probe optimisation
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G06F 19/18 - for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
• G06F 19/28 - for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G06F 19/24 - for machine learning, data mining or biostatistics, e.g. pattern finding, knowledge discovery, rule extraction, correlation, clustering or classification
• G06F 19/10 - Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology (in silico methods of screening virtual chemical libraries C40B 30/02;in silico or mathematical methods of creating virtual chemical libraries C40B 50/02)
• G06F 19/18 - for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
• C40B 30/02 - In silico screening
• C40B 60/12 - Apparatus specially adapted for use in combinatorial chemistry or with libraries for screening libraries
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G06F 19/24 - for machine learning, data mining or biostatistics, e.g. pattern finding, knowledge discovery, rule extraction, correlation, clustering or classification
• G06F 19/10 - Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology (in silico methods of screening virtual chemical libraries C40B 30/02;in silico or mathematical methods of creating virtual chemical libraries C40B 50/02)
• G06F 19/18 - for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
• C40B 30/02 - In silico screening
• C40B 60/12 - Apparatus specially adapted for use in combinatorial chemistry or with libraries for screening libraries
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G06F 19/24 - for machine learning, data mining or biostatistics, e.g. pattern finding, knowledge discovery, rule extraction, correlation, clustering or classification
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• G06F 19/10 - Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology (in silico methods of screening virtual chemical libraries C40B 30/02;in silico or mathematical methods of creating virtual chemical libraries C40B 50/02)
• G06F 19/18 - for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
• C40B 30/02 - In silico screening
• C40B 60/12 - Apparatus specially adapted for use in combinatorial chemistry or with libraries for screening libraries
• G06F 19/22 - for sequence comparison involving nucleotides or amino acids, e.g. homology search, motif or Single-Nucleotide Polymorphism [SNP] discovery or sequence alignment
• G06F 19/20 - for hybridisation or gene expression, e.g. microarrays, sequencing by hybridisation, normalisation, profiling, noise correction models, expression ratio estimation, probe design or probe optimisation

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G06F 19/24 - for machine learning, data mining or biostatistics, e.g. pattern finding, knowledge discovery, rule extraction, correlation, clustering or classification
• G06F 19/10 - Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology (in silico methods of screening virtual chemical libraries C40B 30/02;in silico or mathematical methods of creating virtual chemical libraries C40B 50/02)
• G06F 19/18 - for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
• C40B 30/02 - In silico screening
• C40B 60/12 - Apparatus specially adapted for use in combinatorial chemistry or with libraries for screening libraries
• G06F 19/22 - for sequence comparison involving nucleotides or amino acids, e.g. homology search, motif or Single-Nucleotide Polymorphism [SNP] discovery or sequence alignment

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments that have likely benefit for a cancer, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease. The molecular profiling can be used to identify likely have lack of benefit for treating the cancer.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G06F 19/18 - for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G06F 19/24 - for machine learning, data mining or biostatistics, e.g. pattern finding, knowledge discovery, rule extraction, correlation, clustering or classification
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• G06F 19/10 - Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology (in silico methods of screening virtual chemical libraries C40B 30/02;in silico or mathematical methods of creating virtual chemical libraries C40B 50/02)
• C40B 30/02 - In silico screening
• C40B 60/12 - Apparatus specially adapted for use in combinatorial chemistry or with libraries for screening libraries
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G06F 19/24 - for machine learning, data mining or biostatistics, e.g. pattern finding, knowledge discovery, rule extraction, correlation, clustering or classification
• G06F 19/10 - Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology (in silico methods of screening virtual chemical libraries C40B 30/02;in silico or mathematical methods of creating virtual chemical libraries C40B 50/02)
• G06F 19/18 - for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
• C40B 30/02 - In silico screening
• C40B 60/12 - Apparatus specially adapted for use in combinatorial chemistry or with libraries for screening libraries
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

A system and method for determining individualized medical intervention for a particular disease state, and especially for cancers, that includes the molecular profiling of a biological sample from the patient, determining whether any molecular findings including one or more genes, one or more gene expressed proteins, one or more molecular mechanisms, and/or combinations of such exhibit a change in expression compared to a reference, and identifying a non-specific disease therapy or agent capable of interacting with the genes, gene expressed proteins, molecular mechanisms, or combinations of such molecular findings that exhibited a change in expression.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G06F 19/18 - for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
• G06F 19/20 - for hybridisation or gene expression, e.g. microarrays, sequencing by hybridisation, normalisation, profiling, noise correction models, expression ratio estimation, probe design or probe optimisation
• G06F 19/28 - for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures

Abstract

A system and method for determining individualized medical intervention for a particular disease state, and especially for cancers, that includes the molecular profiling of a biological sample from the patient, determining whether any molecular findings including one or more genes, one or more gene expressed proteins, one or more molecular mechanisms, and/or combinations of such exhibit a change in expression compared to a reference, and identifying a non-specific disease therapy or agent capable of interacting with the genes, gene expressed proteins, molecular mechanisms, or combinations of such molecular findings that exhibited a change in expression.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G06F 19/18 - for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
• G06F 19/20 - for hybridisation or gene expression, e.g. microarrays, sequencing by hybridisation, normalisation, profiling, noise correction models, expression ratio estimation, probe design or probe optimisation
• G06F 19/28 - for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures

Abstract

A system and method for determining individualized medical intervention for a particular disease state, and especially for cancers, that includes the molecular profiling of a biological sample from the patient, determining whether any molecular findings including one or more genes, one or more gene expressed proteins, one or more molecular mechanisms, and/or combinations of such exhibit a change in expression compared to a reference, and identifying a non-specific disease therapy or agent capable of interacting with the genes, gene expressed proteins, molecular mechanisms, or combinations of such molecular findings that exhibited a change in expression.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G06F 19/18 - for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
• G06F 19/20 - for hybridisation or gene expression, e.g. microarrays, sequencing by hybridisation, normalisation, profiling, noise correction models, expression ratio estimation, probe design or probe optimisation
• G06F 19/28 - for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures

Goods & Services

Computer software. Providing medical and scientific research information in the field of phamaceuticals and clinical trials, namely assessment of clinical data; technical data analysis services, namely annotation of individualized clinical data with published clinical data results. Medical screening services in the field of cancer; medical diagnostic testing, monitoring and reporting services; pathology diagnostic services; prognostic analysis services; theranostic analysis services; molecular diagnostic services.

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.

IPC Classes  ?

• C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease. The cancer can be an ovarian cancer.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Goods & Services

Medical research, namely, assessment of clinical data; Medical research, namely, annotation of individualized clinical data with published clinical data results medical screening services in the field of cancer; medical diagnostic testing, monitoring and reporting services; pathology diagnostic services for medical purposes; prognostic analysis services for medical purposes; theranostic analysis services for medical purposes; molecular diagnostic services for medical purposes

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. The molecular profiling can be used to provide a diagnosis, prognosis, or theranosis for the disease, such as identifying a candidate treatment. The methods can detect overexpression of SPARC and HSP90. The cancer can be, e.g., a renal cell carcinoma or an interdigitating dendritic cell sarcoma.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G06F 19/10 - Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology (in silico methods of screening virtual chemical libraries C40B 30/02;in silico or mathematical methods of creating virtual chemical libraries C40B 50/02)

Abstract

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Provided herein are methods and systems for identifying a therapeutic for an individual, such as a therapeutic not previously identified for treating the individual. The therapeutic can be identified by molecular profiling, such as determining the biomarker patterns or signature sets of a biological sample of an individual.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/12 - Genes encoding animal proteins
• G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)